Climb Bio Stock Performance
| CLYM Stock | 5.19 0.03 0.58% |
Climb Bio holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.8, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Climb Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Climb Bio is expected to be smaller as well. Use Climb Bio potential upside, and the relationship between the total risk alpha and kurtosis , to analyze future returns on Climb Bio.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Climb Bio are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Climb Bio displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.78 | Five Day Return 7.05 | Year To Date Return 37.6 | Ten Year Return (34.10) | All Time Return (34.10) |
1 | Q1 Earnings Estimate for Climb Bio Issued By William Blair | 11/10/2025 |
2 | Disposition of 20440000 shares by Ra Capital Management, L.p. of Climb Bio subject to Rule 16b-3 | 12/11/2025 |
3 | Data-Rich Year Ahead - Will 2026 Readouts Lift Climb Bio Higher - RTTNews | 12/15/2025 |
4 | H.C. Wainwright raises Climb Bio stock price target to 11 on budoprutug progress - Investing.com Nigeria | 12/18/2025 |
5 | Climb Bio Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 12/24/2025 |
6 | Freedom Capital Markets initiates Buy rating on Climb Bio stock with 9 target - Investing.com | 12/30/2025 |
7 | Acquisition by Ra Capital Management, L.p. of 7111 shares of Climb Bio at 3.5 subject to Rule 16b-3 | 01/05/2026 |
8 | Acquisition by Driscoll Cindy of 100000 shares of Climb Bio at 3.81 subject to Rule 16b-3 | 01/06/2026 |
9 | Disposition of 5000 shares by Emily Pimblett of Climb Bio subject to Rule 16b-3 | 01/28/2026 |
| Begin Period Cash Flow | 93.1 M | |
| Total Cashflows From Investing Activities | -121.1 M |
Climb Bio Relative Risk vs. Return Landscape
If you would invest 205.00 in Climb Bio on October 31, 2025 and sell it today you would earn a total of 311.00 from holding Climb Bio or generate 151.71% return on investment over 90 days. Climb Bio is currently generating 1.8704% in daily expected returns and assumes 8.3668% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than Climb, and 63% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Climb Bio Target Price Odds to finish over Current Price
The tendency of Climb Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.19 | 90 days | 5.19 | about 5.07 |
Based on a normal probability distribution, the odds of Climb Bio to move above the current price in 90 days from now is about 5.07 (This Climb Bio probability density function shows the probability of Climb Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Climb Bio has a beta of 0.8 suggesting as returns on the market go up, Climb Bio average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Climb Bio will be expected to be much smaller as well. Moreover Climb Bio has an alpha of 1.6877, implying that it can generate a 1.69 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Climb Bio Price Density |
| Price |
Predictive Modules for Climb Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Climb Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Climb Bio is not an exception. The market had few large corrections towards the Climb Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Climb Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Climb Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.69 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 1.30 | |
Ir | Information ratio | 0.21 |
Climb Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Climb Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Climb Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Climb Bio is way too risky over 90 days horizon | |
| Climb Bio appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (73.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Climb Bio generates negative cash flow from operations | |
| Latest headline from MacroaxisInsider: Disposition of 5000 shares by Emily Pimblett of Climb Bio subject to Rule 16b-3 |
Climb Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Climb Stock often depends not only on the future outlook of the current and potential Climb Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Climb Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.2 M | |
| Cash And Short Term Investments | 150.9 M |
Climb Bio Fundamentals Growth
Climb Stock prices reflect investors' perceptions of the future prospects and financial health of Climb Bio, and Climb Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Climb Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | 266.19 M | ||||
| Shares Outstanding | 47.74 M | ||||
| Price To Book | 1.99 X | ||||
| EBITDA | (30.36 M) | ||||
| Net Income | (73.9 M) | ||||
| Total Debt | 532 K | ||||
| Book Value Per Share | 2.60 X | ||||
| Cash Flow From Operations | (15.56 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Market Capitalization | 351.83 M | ||||
| Total Asset | 217.19 M | ||||
| Retained Earnings | (229.88 M) | ||||
| Working Capital | 149.94 M | ||||
About Climb Bio Performance
By examining Climb Bio's fundamental ratios, stakeholders can obtain critical insights into Climb Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Climb Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.31) | (0.33) |
Things to note about Climb Bio performance evaluation
Checking the ongoing alerts about Climb Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Climb Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Climb Bio is way too risky over 90 days horizon | |
| Climb Bio appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (73.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Climb Bio generates negative cash flow from operations | |
| Latest headline from MacroaxisInsider: Disposition of 5000 shares by Emily Pimblett of Climb Bio subject to Rule 16b-3 |
- Analyzing Climb Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Climb Bio's stock is overvalued or undervalued compared to its peers.
- Examining Climb Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Climb Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Climb Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Climb Bio's stock. These opinions can provide insight into Climb Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.